PI3K/Akt/mTOR · target hub

EIF4EBP2

Eukaryotic translation initiation factor 4E-binding protein 2 (EIF4EBP2)

EIF4EBP2 is a mTORC1 translational output on the PI3K/Akt/mTOR axis. Repressor of translation initiation involved in synaptic plasticity, learning and memory formation (PubMed:30765518). Regulates EIF4E activity by preventing its assembly into the eIF4F complex: hypophosphorylated form of EIF4EBP2 competes with EIF4G1/EIF4G3 and strongly binds to … It is indexed under "4E-BPs & eIF4F assembly" on our pathway page for antibodies, inhibitors, and assay guidance.

Back to pathway overviewSearch: EIF4EBP2UniProt (Q13542)

Research notes

  • Combine with other genes in the same hub block via genetics or pharmacology to test non-redundant roles of EIF4EBP2.
  • Annotate PIK3CA/PTEN and upstream RTK–Ras context when reading p-AKT, mTORC1/2, or lipid outputs.
  • Verify antibody clone, phospho-site, and stimulation; include KD/KO or inhibitor controls.

On the pathway hub (sections)

Genetic lesions & expression context (quick reference)

Type / exampleDomain / context (brief)
Expression contextTissue/cell-type–dependent expression
Rare variantsSporadic variants—require functional validation
Pathway couplingCo-occurs with neighboring nodes on the hub

Naming and prevalence vary by cohort and assay—annotate clinically with COSMIC, ClinVar, OncoKB, and datasheets; research context only.

Assay readouts for EIF4EBP2

  • Translation: p-S6K, p-RPS6, 4E-BP phospho/supershift, eIF4F assembly.
  • Polysome profiling or puromycin labeling (advanced readouts).
  • mTORC1 block: rapamycin or ATP-competitive mTOR inhibitors—time courses.
  • Cross-read MAPK/MNK axes where substrates overlap.

EIF4EBP2 experimental notes

Examples below reflect common literature and public resources (e.g., CCLE, DepMap)—validate genotypes, expression, and passage in your own stocks before committing assays.

[1] Cell lines commonly used for EIF4EBP2 studies (examples)

  • Tool lines: HEK293T, HeLa, MCF-7, HCT116, A549—screen by EIF4EBP2 expression and pathway context (CCLE/DepMap).
  • Combine with neighbors (EIF4EBP1, EIF4EBP3, EIF4E, EIF4G1) via KD/pharmacology to test non-redundancy.
  • Overexpression/rescue in HEK293T supports mechanism and IP workflows.
  • Isogenic/CRISPR models separate pathway dependency from bypass survival.

[2] Cell samples for EIF4EBP2 Western blot

  • Whole-cell lysates—optimize RIPA/NP-40 per antibody; phosphatase inhibitors for phospho blots.
  • Stimulation: serum starvation ± insulin/EGF or amino-acid withdrawal/refeed as relevant.
  • Controls: siRNA/shRNA, CRISPR KO, or inhibitors to validate band specificity.
  • Loading: BCA normalization; subcellular fractionation when needed.

[3] Tissue samples for EIF4EBP2 Western blot

  • Matched tumor/adjacent frozen tissues after pathology review.
  • Mouse GEMM or xenografts—mind species antibody cross-reactivity.
  • Primary cells/PDCs when ethically approved.
  • FFPE needs specialized extraction; frozen tissue preferred for phospho work.

[4] Cell samples for EIF4EBP2 immunoprecipitation

  • Tagged overexpression: HEK293T FLAG/HA-EIF4EBP2 for complex capture.
  • Endogenous IP: high-expression lines; often ≥1–5×10⁶ cells per IP.
  • Stimulation: ligand or nutrient treatments enrich interactions—pilot time courses.
  • Controls: isotype IgG, empty vector, KD/KO negatives.

Human tissues and primary cells require ethics/IRB approval; tumors are heterogeneous—record histotype, site, and preservation conditions.

Bypass & related pathways

Models & genetics note

Overexpression vs endogenous EIF4EBP2 can differ in dosage, splicing, and compartmentation—in organoids/PDX, record passage, matrix, and drug history.

Quick search presets

EIF4EBP2EIF4EBP2 antibodyPI3K inhibitormTOR inhibitor

EIF4EBP2-related antibodies (keyword-biased)

Adds EIF4EBP2 keyword bias atop the PI3K/Akt/mTOR antibody pool—if sparse, use presets above or global search.

Neighboring targets (same hub)

EIF4EBP1EIF4EBP3EIF4EEIF4G1EIF4G2EIF4G3EIF4A1EIF4A2

External databases & resources

FAQ

This content supports research reagents and pathway education—not medical advice. Annotate mutations, drug indications, and protocols with authoritative databases, datasheets, and institutional oversight.

Last reviewed: 2026-05-18

Related on this site

See the PI3K/Akt/mTOR hub for neighboring nodes and assay guidance—cross-check MAPK, RTK, metabolism, and autophagy pages as needed.

PI3K/Akt/mTOR·MAPK/ERK·Receptor tyrosine kinase·Metabolism